GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (OSTO:ALZCUR) » Definitions » EV-to-EBITDA

AlzeCure Pharma AB (OSTO:ALZCUR) EV-to-EBITDA : -3.80 (As of Jun. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is AlzeCure Pharma AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AlzeCure Pharma AB's enterprise value is kr140.58 Mil. AlzeCure Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-36.97 Mil. Therefore, AlzeCure Pharma AB's EV-to-EBITDA for today is -3.80.

The historical rank and industry rank for AlzeCure Pharma AB's EV-to-EBITDA or its related term are showing as below:

OSTO:ALZCUR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.74   Med: 0   Max: 2.13
Current: -3.8

During the past 7 years, the highest EV-to-EBITDA of AlzeCure Pharma AB was 2.13. The lowest was -35.74. And the median was 0.00.

OSTO:ALZCUR's EV-to-EBITDA is ranked worse than
100% of 459 companies
in the Biotechnology industry
Industry Median: 8.66 vs OSTO:ALZCUR: -3.80

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-25), AlzeCure Pharma AB's stock price is kr1.875. AlzeCure Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.532. Therefore, AlzeCure Pharma AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


AlzeCure Pharma AB EV-to-EBITDA Historical Data

The historical data trend for AlzeCure Pharma AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzeCure Pharma AB EV-to-EBITDA Chart

AlzeCure Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial 0.55 -3.24 -2.37 -3.35 -4.47

AlzeCure Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.79 -6.79 -5.77 -4.47 -2.54

Competitive Comparison of AlzeCure Pharma AB's EV-to-EBITDA

For the Biotechnology subindustry, AlzeCure Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AlzeCure Pharma AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AlzeCure Pharma AB's EV-to-EBITDA falls into.



AlzeCure Pharma AB EV-to-EBITDA Calculation

AlzeCure Pharma AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=140.581/-36.965
=-3.80

AlzeCure Pharma AB's current Enterprise Value is kr140.58 Mil.
AlzeCure Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-36.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AlzeCure Pharma AB  (OSTO:ALZCUR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

AlzeCure Pharma AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.875/-0.532
=At Loss

AlzeCure Pharma AB's share price for today is kr1.875.
AlzeCure Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.532.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


AlzeCure Pharma AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AlzeCure Pharma AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AlzeCure Pharma AB (OSTO:ALZCUR) Business Description

Traded in Other Exchanges
Address
Halsovagen 7, Novum, Floor 7, Elevator D, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drug within its three research platforms NeuroRestore, Alzstatin, Painless.

AlzeCure Pharma AB (OSTO:ALZCUR) Headlines

No Headlines